Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2020
MARKET OUTLOOK
Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional therapies or for the first-line treatment of very severe disease. Takeda’s CAM inhibitor, Entyvio, and Janssen’s IL-12 / IL-23 inhibitor, Stelara, are alternative options, especially for TNF-α-refractory patients. In addition, Pfizer’s JAK inhibitor, Xeljanz / Xeljanz XR, is the first oral agent approved (2018) to treat UC. These three newer drugs are not approved for pediatric UC, but, given the limited number of therapies available for pediatric patients who fail TNF-α inhibitors, physicians may turn to them as last-line options.
QUESTIONS ANSWERED
- What percentage of pediatric UC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
- How have Entyvio, Stelara, and Xeljanz been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of pediatric UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
